Latest news

• Janssen’s Tremfya receives positive results for active psoriatic arthritis

  Following a newly published network meta-analysis (NMA), Janssen Pharmaceutical Companies – a branch of Johnson &Johnson – announced that its psoriatic arthritis (PsA) therapy Tremfya (guselkumab) has ranked highest overall for skin ... In its

• MorphoSys expands oncology pipeline with $1.7bn acquisition of Constellation Pharmaceuticals

  In return, Royalty Pharma will gain the rights to receive 100% of MorphoSys’ royalties on net sales of its commercial drug Tremfya (guselkumab), as well as 80% of future royalties and

• AbbVie lauds head-to-head win for Skyrizi versus Cosentyx

  On paper Skyrizi is actually a closer competitor to Johnson &Johnson's Tremfya (guselkumab), which also targets IL-23, but there’s little doubt that – sales-wise at least – Cosentyx is ... Tremfya, which made $742m for J&J in the first nine months

• J&J splashes $750m on anti-inflammatory drug bermekimab

  J&J already has high stakes in the anti-inflammatory market, with its blockbuster IL-12/IL-23 inhibitor blockbuster Stelara (ustekinumab) and follow-up Tremfya (guselkumab). ... loss. If it can win approval, Tremfya will become the first selective IL-23

• Novartis’ Cosentyx misses the mark in Humira head-to-head

  This includes Johnson &Johnson’s Tremfya (guselkumab), AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Taltz (ixekizumab) and Pfizer’s Xeljanz (tofacitinib citrate).